The RTOG Outcomes Model: Economic end points and measures

Expert Opinion on Pharmacotherapy

Volumn 5, Issue 3, 2004, Pages 513-519

  Konski, Andre ^a   Watkins Bruner, Deborah ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

Clinical trials; Economic analysis

Indexed keywords

ANTINEOPLASTIC AGENT; CARMUSTINE; FLUTAMIDE; GOSERELIN;

CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL RESEARCH; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; ECONOMIC EVALUATION; GLIOBLASTOMA; HEAD AND NECK CANCER; HEALTH CARE ORGANIZATION; HUMAN; LUNG NON SMALL CELL CANCER; MEDICAL DOCUMENTATION; MONTE CARLO METHOD; OUTCOMES RESEARCH; PATIENT CARE; PROBABILITY; PROSTATE CANCER; REVIEW;

CLINICAL TRIALS; COST-BENEFIT ANALYSIS; ENDPOINT DETERMINATION; HUMANS; MODELS, ECONOMIC; NEOPLASMS; RADIATION ONCOLOGY;

EID: 1542715171     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.5.3.513     Document Type: Review

References (16)

1. JAAKKIMAINEN L, GOODWIN PJ, PATER J, WARDE P, MURRAY N, RAPP E: Counting the costs of chemotherapy in a National Cancer Institute of Canada randomized trial in nonsmall-cell lung cancer. J. Clin. Oncol. (1990) 8(8):1301-1309.
2. BRUNER DW, MOVSAS B, KONSKI A et al.: Outcomes Research in Cancer Clinical Trial Cooperative Groups: The RTOG Model. Qual. Life Res. (2004) (In Press).
3. NEYMARK N, ADRIAENSSEN I, GORLIA T, CALEO S, BOLLA M: Estimating survival gain for economic evaluations with survival time as principal endpoint: A cost-effectiveness analysis of adding early hormonal therapy to radiotherapy in patients with locally advanced prostate cancer. Health Econ. (2002) 11(3):233-248.
4. NEYMARK N, KIEBERT W, TORFS K et al.: Methodological and statistical issues of quality of life (QoL) and economic evaluations in cancer clinical trials: Report of a workshop. Eur. J. Cancer (1998) 9:1317-1333.
5. OWEN JB, GRIGSBY PW, CALDWELL TM et al.: Can costs be measured and predicted by modeling within a cooperative clinical trials group? Economic methodologic pilot studies of the radiation therapy oncology group (RTOG) studies 90-03 and 91-04. Int. J. Radiat. Oncol. Biol. Phys. (2001) 49(3):633-639.
6. MURRAY KJ, NELSON DF, SCOTT C et al.: Quality-adjusted survival analysis of malignant glioma. Patients treated with twice-daily radiation (RT) and carmustine: A report of Radiation Therapy Oncology Group (RTOG) 83-02. Int. J. Radiat. Oncol. Biol. Phys. (1995) 31(3):453-459.
7. KONSKI A, BRACY P, WEISS S, GRIGSBY P: Cost-utility analysis of a malignant glioma protocol. Int. J. Radiat. Oncol. Biol. Phys. (1997) 39(3):575-578.
8. MOVSAS B, SCOTT C, SAUSE W et al.: The benefit of treatment intensification is age and histology-dependent in patients with locally advanced non-small cell lung cancer (NSCLC): A quality-adjusted survival analysis of radiation therapy oncology group (RTOG) chemoradiation studies. Int. J. Radiat. Oncol. Biol. Phys. (1999) 45(5):1143-1149.
9. KONSKI A, SCOTT C, MOVSAS B et al.: Cost-utility analysis of various treatments for non-small cell carcinoma of the lung. Eur. J. Cancer (2000) 36(3):19.
10. KONSKI A, SCOTT C, ANG KK, FU KK: Cost-utility analysis of RTOG 90-03: Phase III randomized study comparing altered fractionation to standard fractionation radiotherapy for locally advanced head neck squamous cell carcinoma. Int. J. Radiat. Oncol. Biol. Phys. (2001) 51(S1):48.
11. SHIPLEY WU, LU JD, PILEPICH MV et al.: Effect of a short course of neoadjuvant hormonal therapy on the response to subsequent androgen suppression in prostate cancer patients with relapse after radiotherapy: A secondary analysis of the randomized protocol RTOG 86-10. Int. J. Radiat. Oncol. Biol. Phys. (2002) 54(5):1302-310.
12. PILEPICH MV, WINTER K, JOHN MJ et al.: Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int. J. Radiat. Oncol. Biol. Phys. (2001) 50(5):1243-252.
13. KONSKI AA, SHERMAN E, KRAHN M et al.: Monte Carlo simulation of a Markov Model for a Phase III clinical trial evaluating the addition of total androgen suppression (TAS) to radiation versus radiation alone for locally advanced prostate cancer (RTOG 86-10). Int. J. Radiat. Oncol. Biol. Phys. (2003) 57(2 Suppl.):S215-S216.
14. NAIMARK D, KRAHN MD, NAGLIE G, REDELMEIER DA, DETSKY AS: Primer on medical decision analysis: Part 5 - Working with Markov processes. Med. Decis. Making (1997) 17(2):152-159.
15. KRAHN M, RITVO P, IRVINE J et al.: Patient and community preferences for outcomes in prostate cancer: Implications for clinical policy. Med. Care (2003) 41(1):153-164.
16. HARTSELL WF, SCOTT C, BRUNER DW et al.: Phase III randomized trial of 8 Gy in 1 fraction versus 30 Gy in 10 fractions for palliation of painful bone metastases: Preliminary results of RTOG 97-14. Int. J. Radiat. Oncol. Biol. Phys. (2003) 57(2 Suppl.):S124.